Heidelberg Pharma to Present New Data on its Proprietary ATAC Technology Platform at the AACR Annual Meeting 2021
Heidelberg Pharma AG announced today that it will present preclinical data on its novel ATAC candidates HDP-102 and HDP-103 as well as data on synergistic effects of ATACs with checkpoint inhibitors at the American Association for Cancer Research (AACR) 2021 Annual Meeting. The meeting will be held in a virtual format from April 10 – 15, 2021.